News Column

Telegraph Hill Partners Names Paul D. Grossman as Venture Partner

February 14, 2014

Telegraph Hill Partners (THP), a venture capital and growth equity firm dedicated exclusively to life science and healthcare investing, announced the addition of Paul D. Grossman, Ph.D. to its investment team as a Venture Partner.

Dr. Grossman, a 32-year veteran of the life science industry, has experience within the laboratory tools and instruments sector. Most recently, Dr. Grossman was Head of Global Strategy and Corporate Development at Life Technologies, Inc. In that role, he was responsible for spearheading the company's corporate strategy, licensing, business development and acquisition activities. Dr. Grossman held the same position at Invitrogen Corp. prior to the merger with Applied Biosystems in 2008. Prior to joining Invitrogen, Dr. Grossman held a variety of leadership roles during his more than 25 years at Applied Biosystems, including research scientist, patent attorney, Vice President of Intellectual Property and Vice President of Strategy and Business Development.

"We are delighted to have Paul join our team. For over three decades Paul has been one of the leading innovators in the life science industry, initially as a scientist and later as a business strategist. Paul's experience and insights will contribute to our investment decisions as we deploy our new fund, and will be a tremendous benefit to our portfolio companies," said Matt Mackowski, Chairman of THP.

Dr. Grossman will be located in San Diego focused on developing new strategies, sourcing new opportunities and supporting the growth plans of existing THP portfolio companies.

More Information:

http://www.telegraphhillpartners.com

((Comments on this story may be sent to newsdesk@closeupmedia.com))


For more stories on investments and markets, please see HispanicBusiness' Finance Channel



Source: Manufacturing Close - Up


Story Tools